Peginterferon alfa-2a clinical trials
Also written Pegasys and Pegylated interferon alfa-2a.
How each study uses peginterferon alfa-2a is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the peginterferon alfa-2a studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Oct 2002 · PEGASYS · BLA 103964 (FDA, Drugs@FDA)
- European Union
- 20 Jun 2002 · Pegasys · EMEA/H/C/000395 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
218 studies that test it; most in 2005 (22)
| Year | Studies |
|---|---|
| 2000 | 2 |
| 2001 | 3 |
| 2002 | 6 |
| 2003 | 15 |
| 2004 | 19 |
| 2005 | 22 |
| 2006 | 18 |
| 2007 | 20 |
| 2008 | 8 |
| 2009 | 15 |
| 2010 | 7 |
| 2011 | 16 |
| 2012 | 20 |
| 2013 | 6 |
| 2014 | 3 |
| 2015 | 13 |
| 2016 | 10 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 100 · Other 119
Hoffmann-La Roche (64) · National Taiwan University Hospital (9) · Vertex Pharmaceuticals Incorporated (8) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Kaohsiung Medical University Chung-Ho Memorial Hospital (6) · Beijing Ditan Hospital (5) · Bristol-Myers Squibb (4)
Often tested with
Tested in the same studies.
Ribavirin (81) · Telaprevir (10) · Tenofovir (6) · Interferon alpha-2 (4) · Entecavir (4) · Daclatasvir (3) · Peginterferon lambda-1a (3) · EYP001A (2)
Related medicines
As reviewed, each with the page that says it.
- One of Interferons source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test peginterferon alfa-2a.
- Jan 2027AlloHCT With PegINFa for MyelofibrosisPhase 1 · University of Utah
- Apr 2027A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BPhase 1 · IntegerBio
Studies
Open first, then newest update. How each study uses peginterferon alfa-2a is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 219
- AlloHCT With PegINFa for MyelofibrosisRecruitingPhase 1University of UtahNCT05535764Written as Pegylated interferon alpha2a
- A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BRecruitingPhase 1IntegerBioNCT07389044Written as Peginterferon Alfa-2A
- Effect of Low-dose Interferon-alfa2a on Peri-operative Immune SuppressionRecruitingPhase 2Zealand University HospitalNCT04798612Written as Pegasys
- Interferon Alfa Therapy Based on Th17 Profile in Membranous NephropathyTerminatedPhase 2Centre Hospitalier Universitaire de NiceNCT05941845Written as Peginterferon Alfa-2A 180 MCG/ML Injectable Solution
- Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-infected PatientsCompletedPhase 2University Hospital, BordeauxNCT00221650Written as Peginterferon alfa2a
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous AngiosarcomaWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05799612Written as PEGYLATED-INTERFERON ALPHA-2A
- HBsAg Loss Adding Pegylated Interferon in HBeAg-negative PatientsCompletedNot applicableJosé Antonio CarrionNCT02743182Written as Pegylated interferon alfa-2a
- Peg-interferon for Inactive Chronic Hepatitis B CarriersCompletedPhase 2/3Seng Gee LimNCT02992704Written as Peginterferon Alfa-2A
- Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General HospitalCompletedPhase 4Nanogen Pharmaceutical Biotechnology Joint Stock CompanyNCT06922643Written as Peginterferon Alfa-2A
- SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).CompletedPhase 2Hoffmann-La RocheNCT00442572Written as PEGASYS [peginterferon alfa-2a]
- Switching Regimen in Treating Cirrhotic HCV GT1b SubjectsCompletedPhase 2Humanity and Health Research CentreNCT02583685Written as PR4 + LDV/SOF + ASV 4 wk
- Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)CompletedPhase 2Gilead SciencesNCT03852433Written as Peginterferon Alfa-2a (PEG-IFN alfa)
- Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral TherapyCompletedPhase 1/2Massachusetts General HospitalNCT02471430Written as Pegylated Interferon-alpha2a
- Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/RelapsersTerminatedEarly Phase 1University of NebraskaNCT00882193Written as Peginterferon alpha 2a
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C InfectionCompletedPhase 4Tanta UniversityNCT02992457Written as Pegylated-interferon alfa-2a
- Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive PatientsWithdrawnNot applicableUniversity of NebraskaNCT00571714Written as Peginterferon alpha-2a and ribavirin
- Cemiplimab/Peg-Interferon-α in Advanced CSCCWithdrawnPhase 1Baptist Health South FloridaNCT05729139Written as PEG-IFN alfa-2a
- Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis BCompletedPhase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT01369212Written as Peginterferon-alfa 2a and tenofovir
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2aCompletedPhase 3Eiger BioPharmaceuticalsNCT03719313Written as PEG IFN-alfa-2a
- A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis BCompletedPhase 3Hoffmann-La RocheNCT01519960Written as peginterferon alfa-2a [Pegasys]
See all 219 studies that test peginterferon alfa-2a →
Given beside what is tested · 133 — peginterferon alfa-2a is usual care or a partner of the new treatment
- DOC1021 Dendritic Cell Immunotherapy for Refractory MelanomaRecruitingPhase 1/2Diakonos Oncology CorporationNCT07288112Written as pIFN (peginterferon alfa-2a)
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis BActive, not recruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT06092333Written as VIR-2218 and peginterferon alfa-2a
- Lonafarnib With and Without Ritonavir in HDV (LOWR-1)CompletedPhase 2EIT Pharma, Inc.NCT02430181Written as peginterferon alfa-2a
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionCompletedPhase 2Arbutus Biopharma CorporationNCT04980482Written as Peg-IFNα-2a
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionCompletedPhase 2Vir Biotechnology, Inc.NCT04412863Written as pegylated interferon-alfa 2a
- Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin RegimenCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT01332955Written as pegIFN alfa-2a
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)TerminatedPhase 2Arrowhead PharmaceuticalsNCT02577029Written as pegylated interferon alpha 2a
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedPhase 3Tanabe Pharma CorporationNCT01753557Written as PEG-IFN alfa-2a
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /RibavirinTerminatedPhase 3Anna CrucetaNCT01718301Written as Peginterferon alfa-2a
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04439539Written as PegIFN-alpha-2a
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04585789Written as PegIFN-alpha-2a (Optional)
- A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy ParticipantsTerminatedPhase 1Bristol-Myers SquibbNCT06144697Written as Pegasys
- A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04667104Written as PegIFN-alpha2a
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus InfectionTerminatedPhase 2Janssen Research & Development, LLCNCT05005507Written as PegIFN-alpha-2a
- Telaprevir in Genotype 3 HCVCompletedPhase 4Queen Mary University of LondonNCT02087111Written as 40 Kd Pegylated interferon alfa 2a
- High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCVCompletedPhase 3Foundation for Liver ResearchNCT00381953Written as Peginterferon alfa-2a
- A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT00758043Written as peginterferon alfa-2a
- Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China IIICompletedPhase 3Ascletis Pharmaceuticals Co., Ltd.NCT03020082Written as peginterferon alfa-2a
- A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus InfectionTerminatedPhase 2Vertex Pharmaceuticals IncorporatedNCT01080222Written as peginterferon-alfa-2a
- A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1Hoffmann-La RocheNCT02174172Written as PEG-interferon alfa-2a
Showing 20 of 133.
As the comparator · 27 — what is tested is compared with peginterferon alfa-2a
- A Phase 1b/2a Study of SC Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis CCompletedPhase 1/2HanAll BioPharma Co., Ltd.NCT01194037Written as Peginterferon alfa-2a
- Single Dose Escalation Study of P1101 in Healthy Adult Male SubjectsCompletedPhase 1PharmaEssentiaNCT05129644Written as Pegasys
- Dose Finding Study of Pegylated-P-Interferon-alpha-2b(P1101) in Treatment-Naive Subjects With Hepatitis C Virus Genotype 1 InfectionCompletedPhase 2PharmaEssentiaNCT01587586Written as PEGASYS 180 µg Q1W
- Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B PatientCompletedPhase 1/2Tianjin SinoBiotech Ltd.NCT03294798Written as Pegasys
- A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)TerminatedPhase 3Merck Sharp & Dohme LLCNCT01641926Written as PEGASYS™
- An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis CCompletedPhase 3BiocadNCT01889433Written as Pegasys
- A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment BeforeCompletedPhase 3AbbVieNCT01854697Written as Pegylated Interferon alpha 2-a (PegIFN)
- Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)CompletedPhase 3Merck Sharp & Dohme LLCNCT00081770Written as PEGASYS (peginterferon alfa-2a)
- A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHBStatus unknownPhase 1/2Third Affiliated Hospital, Sun Yat-Sen UniversityNCT02615639Written as IFN-a-2a
- Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e AntigenCompletedPhase 2Bristol-Myers SquibbNCT01204762Written as pegIFNα-2a
- Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinCompletedPhase 2Bristol-Myers SquibbNCT01309932Written as Pegylated Interferon Alfa-2a (pegIFNα-2a)
- Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis CCompletedPhase 3Beijing Kawin Technology Share-Holding Co., Ltd.NCT01903278Written as Pegasys /RBV
- Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis BCompletedPhase 3Xiamen Amoytop Biotech Co., Ltd.NCT01760122Written as Pegasys
- Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis CCompletedPhase 3Bristol-Myers SquibbNCT01754974Written as Peginterferon alfa-2a
- Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B PatientsCompletedPhase 1/2Beijing Bio-Fortune Ltd.NCT01997944Written as Pegasys
- A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis CCompletedPhase 2Beijing Kawin Technology Share-Holding Co., Ltd.NCT01908335Written as Pegasys /RBV
- Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C PatientsCompletedPhase 3Xiamen Amoytop Biotech Co., Ltd.NCT01581398Written as Pegasys
- Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult SubjectsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01504581Written as Pegasys
- Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)Status unknownPhase 1/2Hanmi Pharmaceutical Company LimitedNCT02057887Written as Pegasys
- Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3CompletedPhase 3Human Genome Sciences Inc.NCT00411385Written as peginterferon alfa-2a
Showing 20 of 27.
Codes
What other systems call peginterferon alfa-2a · ClinicalTrials.gg INT003922
- MeSH (NLM) C100416peginterferon alfa-2aConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Q46947FE7KPEGINTERFERON ALFA-2AConfirmed FDA, NLM, Wikidata
- RxNorm 120608Confirmed FDA, Wikidata
- Wikidata Q420056peginterferon alfa-2aConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C33987Peginterferon Alfa-2aOne source FDA
- DrugBank DB00008One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C100416 | peginterferon alfa-2a | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Q46947FE7K | PEGINTERFERON ALFA-2A | Confirmed FDA, NLM, Wikidata |
| RxNorm | 120608 | — | Confirmed FDA, Wikidata |
| Wikidata | Q420056 | peginterferon alfa-2a | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C33987 | Peginterferon Alfa-2a | One source FDA |
| DrugBank | DB00008 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.